Computational insights into the stereo-selectivity of catechins for the inhibition of the cancer therapeutic target EGFR kinase

The epidermal growth factor receptor (EGFR) plays a crucial role in regulating cellular growth and survival, and its dysregulation is implicated in various cancers, making it a prime target for cancer therapy. Natural compounds known as catechins have garnered attention as promising anticancer agents. These compounds exert their anticancer effects through diverse mechanisms, primarily by inhibiting receptor tyrosine kinases (RTKs), a protein family that includes the notable member EGFR. Catechins, characterized by two chiral centers and stereoisomerism, demonstrate variations in chemical and physical properties due to differences in the spatial orientation of atoms. Although previous studies have explored the membrane fluidity effects and transport across cellular membranes, the stereo-selectivity of catechins concerning EGFR kinase inhibition remains unexplored. In this study, we investigated the stereo-selectivity of catechins in inhibiting EGFR kinase, both in its wild-type and in the prevalent L858R mutant. Computational analyses indicated that all stereoisomers, including the extensively studied catechin (−)-EGCG, effectively bound within the ATP-binding site, potentially inhibiting EGFR kinase activity. Notably, gallated catechins emerged as superior EGFR inhibitors to their non-gallated counterparts, revealing intriguing binding trends. The top four stereoisomers exhibiting high dock scores and binding energies with wild-type EGFR comprise (−)-CG (−)-GCG (+)-CG, and (−)-EGCG. To assess dynamic behavior and stability, molecular dynamics simulations over 100 ns were conducted for the top-ranked catechin (−)-CG and the widely investigated catechin (−)-EGCG with EGFR kinase. This study enhances our understanding of how the stereoisomeric nature of a drug influences inhibitory potential, providing insights that could guide the selection of specific stereoisomers for improved efficacy inexisting drugs.

[1]  S. Tabrez,et al.  Analysis of some flavonoids for inhibitory mechanism against cancer target phosphatidylinositol 3-kinase (PI3K) using computational tool , 2023, Frontiers in pharmacology.

[2]  Y. Yarden,et al.  L858R emerges as a potential biomarker predicting response of lung cancer models to anti-EGFR antibodies: Comparison of osimertinib vs. cetuximab , 2023, Cell reports. Medicine.

[3]  S. S. Sohrab,et al.  Investigating a Library of Flavonoids as Potential Inhibitors of a Cancer Therapeutic Target MEK2 Using in Silico Methods , 2023, International journal of molecular sciences.

[4]  S. Tabrez,et al.  Targeting a transcription factor NF-κB by green tea catechins using in silico and in vitro studies in pancreatic cancer , 2023, Frontiers in Nutrition.

[5]  Masayuki Yamane,et al.  4″-Sulfation Is the Major Metabolic Pathway of Epigallocatechin-3-gallate in Humans: Characterization of Metabolites, Enzymatic Analysis, and Pharmacokinetic Profiling , 2022, Journal of agricultural and food chemistry.

[6]  M. Rehan,et al.  Exploring the Natural Compounds in Flavonoids for Their Potential Inhibition of Cancer Therapeutic Target MEK1 Using Computational Methods , 2022, Pharmaceuticals.

[7]  Hanadi M. Baeissa,et al.  A Computational Approach Identified Andrographolide as a Potential Drug for Suppressing COVID-19-Induced Cytokine Storm , 2021, Frontiers in Immunology.

[8]  Tadayuki Kou,et al.  Cancer of unknown primary with EGFR mutation successfully treated with targeted therapy directed by clinical next-generation sequencing: a case report , 2020, BMC Cancer.

[9]  S. Mokale,et al.  A network pharmacology-based approach to explore potential targets of Caesalpinia pulcherima: an updated prototype in drug discovery , 2020, Scientific Reports.

[10]  G. Ashraf,et al.  Exploring Flavonoids for Potential Inhibitors of a Cancer Signaling Protein PI3Kγ Kinase Using Computational Methods , 2020, AntiCancer Research.

[11]  G. Mobbili,et al.  Conformational Insight on WT- and Mutated-EGFR Receptor Activation and Inhibition by Epigallocatechin-3-Gallate: Over a Rational Basis for the Design of Selective Non-Small-Cell Lung Anticancer Agents , 2020, International journal of molecular sciences.

[12]  Yunfeng Zhou,et al.  Prognostic value of EGFR 19-del and 21-L858R mutations in patients with non-small cell lung cancer. , 2019, Oncology letters.

[13]  M. Rehan.  Anticancer compound XL765 as PI3K/mTOR dual inhibitor: A structural insight into the inhibitory mechanism using computational approaches , 2019, PloS one.

[14]  D. Ni,et al.  Effect of Stereochemical Configuration on the Transport and Metabolism of Catechins from Green Tea across Caco-2 Monolayers , 2019, Molecules.

[15]  Kranthi Kumar Konidala,et al.  QSAR modeling, pharmacophore-based virtual screening, and ensemble docking insights into predicting potential epigallocatechin gallate (EGCG) analogs against epidermal growth factor receptor , 2019, Journal of receptor and signal transduction research.

[16]  Lei Zhang,et al.  Epigallocatechin gallate (EGCG) suppresses growth and tumorigenicity in breast cancer cells by downregulation of miR-25 , 2019, Bioengineered.

[17]  H. Corke,et al.  Absorption, metabolism, anti-cancer effect and molecular targets of epigallocatechin gallate (EGCG): An updated review , 2018, Critical reviews in food science and nutrition.

[18]  Hasan Mukhtar,et al.  Cancer preventive and therapeutic effects of EGCG, the major polyphenol in green tea , 2018 .

[19]  Tatsuro Watanabe,et al.  Cancer Prevention with Green Tea and Its Principal Constituent, EGCG: from Early Investigations to Current Focus on Human Cancer Stem Cells , 2018, Molecules and cells.

[20]  S. Sigismund,et al.  Emerging functions of the EGFR in cancer , 2017, Molecular oncology.

[21]  M. Rehan.  An Anti‐Cancer Drug Candidate OSI‐027 and its Analog as Inhibitors of mTOR: Computational Insights Into the Inhibitory Mechanisms , 2017, Journal of cellular biochemistry.

[22]  J. Markowitz,et al.  An Appraisal of Drug-Drug Interactions with Green Tea (Camellia sinensis) , 2017, Planta Medica.

[23]  N. Takahashi,et al.  Inhibitory Effects of Eight Green Tea Catechins on Cytochrome P450 1A2, 2C9, 2D6, and 3A4 Activities. , 2016, Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques.

[24]  Shenmin Zhang,et al.  Synergistic Effects of Dietary Natural Products as Anti-Prostate Cancer Agents , 2015, Natural product communications.

[25]  M. Rehan.  A structural insight into the inhibitory mechanism of an orally active PI3K/mTOR dual inhibitor, PKI-179 using computational approaches , 2015 .

[26]  Berk Hess,et al.  GROMACS: High performance molecular simulations through multi-level parallelism from laptops to supercomputers , 2015 .

[27]  E. Yiannakopoulou.  Interaction of Green Tea Catechins with Breast Cancer Endocrine Treatment: A Systematic Review , 2014, Pharmacology.

[28]  N. Chandra,et al.  ABS–Scan: In silico alanine scanning mutagenesis for binding site residues in protein–ligand complex , 2014, F1000Research.

[29]  Pushpendra Singh,et al.  In silico molecular docking study of natural compounds on wild and mutated epidermal growth factor receptor , 2014, Medicinal Chemistry Research.

[30]  F. Gao,et al.  Epigallocatechin gallate inhibits the growth of human lung cancer by directly targeting the EGFR signaling pathway. , 2014, Oncology reports.

[31]  Shadma Parveen,et al.  Anticancer Compound Plumbagin and Its Molecular Targets: A Structural Insight into the Inhibitory Mechanisms Using Computational Approaches , 2014, PloS one.

[32]  C. Pichard,et al.  Green tea polyphenol epigallocatechin-3-gallate (EGCG) as adjuvant in cancer therapy. , 2013, Clinical nutrition.

[33]  M. Frey,et al.  ErbB receptors and their growth factor ligands in pediatric intestinal inflammation , 2013, Pediatric Research.

[34]  S. Barni,et al.  Anti‐EGFR–targeting agents in recurrent or metastatic head and neck carcinoma: A meta‐analysis , 2012, Head & neck.

[35]  Moorthy P Ponnusamy,et al.  Targeting the EGFR signaling pathway in cancer therapy , 2012, Expert opinion on therapeutic targets.

[36]  Roman A. Laskowski,et al.  LigPlot+: Multiple Ligand-Protein Interaction Diagrams for Drug Discovery , 2011, J. Chem. Inf. Model..

[37]  Fei Guan,et al.  Cancer prevention by tea: Evidence from laboratory studies. , 2011, Pharmacological research.

[38]  A. McKenna,et al.  The Mutational Landscape of Head and Neck Squamous Cell Carcinoma , 2011, Science.

[39]  R. Copeland,et al.  Epigallocatechin gallate (EGCG), a major component of green tea, is a dual phosphoinositide-3-kinase/mTOR inhibitor. , 2011, Biochemical and biophysical research communications.

[40]  S. Barni,et al.  Cetuximab and panitumumab in KRAS wild-type colorectal cancer: a meta-analysis , 2011, International Journal of Colorectal Disease.

[41]  William H. Bisson,et al.  Tea catechins as inhibitors of receptor tyrosine kinases: mechanistic insights and human relevance. , 2010, Pharmacological research.

[42]  D. Shin,et al.  Chemoprevention of Head and Neck Cancer with Green Tea Polyphenols , 2010, Cancer Prevention Research.

[43]  Y. Yarden,et al.  Oncogenic mutant forms of EGFR: Lessons in signal transduction and targets for cancer therapy , 2010, FEBS letters.

[44]  R. Erben,et al.  The EGFR network in bone biology and pathology , 2009, Trends in Endocrinology & Metabolism.

[45]  V. Adhami,et al.  Review: Green Tea Polyphenols in Chemoprevention of Prostate Cancer: Preclinical and Clinical Studies , 2009, Nutrition and cancer.

[46]  V. Adhami,et al.  Effective Prostate Cancer Chemopreventive Intervention with Green Tea Polyphenols in the TRAMP Model Depends on the Stage of the Disease , 2009, Clinical Cancer Research.

[47]  R. Singal,et al.  EGFR targeting of solid tumors. , 2007, Cancer control : journal of the Moffitt Cancer Center.

[48]  F. Ciardiello,et al.  Erlotinib in cancer treatment. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

[49]  Matthew Meyerson,et al.  Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity. , 2007, Cancer cell.

[50]  Stuart Thomson,et al.  Kinetic analysis of epidermal growth factor receptor somatic mutant proteins shows increased sensitivity to the epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib. , 2006, Cancer research.

[51]  J. Minna,et al.  Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. , 2006, Journal of the National Cancer Institute.

[52]  L. Kopelovich,et al.  (−)-Epigallocatechin Gallate and Polyphenon E Inhibit Growth and Activation of the Epidermal Growth Factor Receptor and Human Epidermal Growth Factor Receptor-2 Signaling Pathways in Human Colon Cancer Cells , 2005, Clinical Cancer Research.

[53]  G. Williamson,et al.  A review of the health effects of green tea catechins in in vivo animal models. , 2004, The Journal of nutrition.

[54]  Conrad C. Huang,et al.  UCSF Chimera—A visualization system for exploratory research and analysis , 2004, J. Comput. Chem..

[55]  R. Wilson,et al.  EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[56]  G. Scagliotti,et al.  The Biology of Epidermal Growth Factor Receptor in Lung Cancer , 2004, Clinical Cancer Research.

[57]  S. Gabriel,et al.  EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy , 2004, Science.

[58]  Miyako Mochizuki,et al.  Stereospecific effects of catechin isomers on insulin induced lipogenesis in 3T3‐L1 cells , 2004, Phytotherapy research : PTR.

[59]  Jeanelle Boyer,et al.  Nutrition Journal BioMed Central Review Iron supplements: the quick fix with long-term consequences , 2004 .

[60]  G. Peters,et al.  Combination therapy with gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, gemcitabine and cisplatin in patients with advanced solid tumors. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[61]  Liliana Jiménez,et al.  Polyphenols: food sources and bioavailability. , 2004, The American journal of clinical nutrition.

[62]  J. Grandis,et al.  Signaling through the epidermal growth factor receptor during the development of malignancy. , 2004, Pharmacology & therapeutics.

[63]  Renxiao Wang,et al.  Comparative evaluation of 11 scoring functions for molecular docking. , 2003, Journal of medicinal chemistry.

[64]  T. Walle,et al.  Glucuronidation and sulfation of the tea flavonoid (-)-epicatechin by the human and rat enzymes. , 2002, Drug metabolism and disposition: the biological fate of chemicals.

[65]  G. Diggle.  THALIDOMIDE: 40 YEARS ON , 2001, International journal of clinical practice.

[66]  Todd J. A. Ewing,et al.  DOCK 4.0: Search strategies for automated molecular docking of flexible molecule databases , 2001, J. Comput. Aided Mol. Des..

[67]  H. Tsuchiya,et al.  Stereospecificity in membrane effects of catechins. , 2001, Chemico-biological interactions.

[68]  S. Holgate,et al.  Epithelial damage and response. , 2000, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[69]  I. Arts,et al.  Catechin contents of foods commonly consumed in The Netherlands. 2. Tea, wine, fruit juices, and chocolate milk. , 2000, Journal of agricultural and food chemistry.

[70]  F. Chung.  The prevention of lung cancer induced by a tobacco-specific carcinogen in rodents by green and black Tea. , 1999, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[71]  F. Nanjo,et al.  Identification of (-)-epicatechin metabolites and their metabolic fate in the rat. , 1999, Drug metabolism and disposition: the biological fate of chemicals.

[72]  Jen-kun Lin,et al.  Suppression of extracellular signals and cell proliferation through EGF receptor binding by (−)‐epigallocatechin gallate in human A431 epidermoid carcinoma cells , 1997, Journal of cellular biochemistry.

[73]  G. Gibson,et al.  The relationship of quantitative epidermal growth factor receptor expression in non-small cell lung cancer to long term survival. , 1993, British Journal of Cancer.

[74]  H. Inoue,et al.  Immunohistochemical study of glutathione‐related enzymes and proliferative antigens in lung cancer. Relation to cisplatin sensitivity , 1993, Cancer.

[75]  K. Kinzler,et al.  Increased expression of the epidermal growth factor receptor gene in malignant gliomas is invariably associated with gene amplification. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[76]  J. Farndon,et al.  EPIDERMAL-GROWTH-FACTOR RECEPTOR STATUS AS PREDICTOR OF EARLY RECURRENCE OF AND DEATH FROM BREAST CANCER , 1987, The Lancet.

[77]  G. Gibson,et al.  Epidermal growth factor receptors in non-small cell lung cancer. , 1987, British Journal of Cancer.

[78]  R. Derynck,et al.  Loss of growth responsiveness to epidermal growth factor and enhanced production of alpha‐transforming growth factors in ras‐transformed mouse mammary epithelial cells , 1987, Journal of cellular physiology.

[79]  B. Olofsson,et al.  Structure and expression of the chicken epidermal growth factor receptor gene locus. , 1986, European journal of biochemistry.

[80]  B. Gusterson,et al.  Increased EGF receptors on human squamous carcinoma cell lines. , 1986, British Journal of Cancer.

[81]  B. Gusterson,et al.  Cellular localisation of human epidermal growth factor receptor. , 1984, Cell biology international reports.

[82]  P. Walter,et al.  Stereospecific effects of (+)- and (-)-catechin on glycogen metabolism in isolated rat hepatocytes. , 1983, Biochimica et biophysica acta.

[83]  Pravin Vasantrao Gadkari,et al.  Catechins: Sources, extraction and encapsulation: A review , 2015 .

[84]  Chung S. Yang,et al.  Effects of Tea Catechins on Cancer Signaling Pathways. , 2014, The Enzymes.

[85]  S. Misaka,et al.  Effects of green tea catechins on cytochrome P450 2B6, 2C8, 2C19, 2D6 and 3A activities in human liver and intestinal microsomes. , 2013, Drug metabolism and pharmacokinetics.

[86]  Sun Mi Park,et al.  (-)-Catechin promotes adipocyte differentiation in human bone marrow mesenchymal stem cells through PPAR gamma transactivation. , 2009, Biochemical pharmacology.

[87]  C. Angeletti,et al.  Evaluation of epidermal growth factor-related growth factors and receptors and of neoangiogenesis in completely resected stage I-IIIA non-small-cell lung cancer: amphiregulin and microvessel count are independent prognostic indicators of survival. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.